3
Announcements
Trials
Browse
Landscape
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
47
Carcinoma, Hepatocellular
9
Triple Negative Breast Neoplasms
7
Stomach Neoplasms
6
Inflammatory Breast Neoplasms
6
Lymphoma, Large B-Cell, Diffuse
4
Urinary Bladder Neoplasms
3
Non-Muscle Invasive Bladder Neoplasms
3
Esophageal Neoplasms
3
Recurrence
2
Lymphoma
2
Breast Neoplasms, Male
2
Breast Diseases
2
Upper Tract Urothelial Carcinoma
1
Thymoma
1
Small Cell Lung Cancer Extensive Stage
1
Sarcoma
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Postoperative Complications
1
Pancreatic Neoplasms
1
Oesophagogastric Cancer
1
Neoplastic Cells, Circulating
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell
1
Lung Neoplasms
1
Liver Neoplasms
1
Leiomyosarcoma
1
Interventions
Gemcitabine
9
Oxaliplatin
6
Cisplatin
6
Capecitabine
6
durvalumab
4
apatinib
4
S 1 (combination)
4
Irinotecan
4
Immune Checkpoint Inhibitors
4
surufatinib
3
Injections
3
Drug Therapy
3
pembrolizumab
2
lenvatinib
2
camrelizumab
2
Taxes
2
Leucovorin
2
Fluorouracil
2
Docetaxel
2
130-nm albumin-bound paclitaxel
2
tremelimumab
1
toripalimab
1
taxane
1
spartalizumab
1
sintilimab
1
regorafenib
1
manganese chloride
1
irinotecan sucrosofate
1
gimeracil
1
gemcitabine-oxaliplatin regimen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Biliary Tract Neoplasms
×
Epirubicin
×
Clear all
NCT03668418
2018-09-12
xenoZ
University of Pisa
Unknown
120 enrolled